Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66%… Jul 20, 2022
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of… Apr 19, 2022
Awakn Life Sciences’ Professor Celia Morgan Named One Of The Most Influential Women In The Psychedelics Industry Feb 15, 2022
Ketamine Expert Dr. Reid Robison On Clinical Trials, Ketamine For Eating Disorders, And Novamind’s Plans For Growth Jan 26, 2022
